Patents by Inventor Michael Guarnieri

Michael Guarnieri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12090151
    Abstract: An injectable lipid-based suspension of buprenorphine providing one to seven days of pain alleviation has been developed. A method of manufacturing an injectable buprenorphine formulation providing about two to three days of pain therapy has been developed. A method of manufacturing an injectable buprenorphine formulation providing about one to seven, preferably two to three, days of pain therapy has been developed. The formulation is made by mixing buprenorphine, glyceryl distearate, and glyceryl tristearate dry powers with a liquid medium chain triglyceride (MCT), such as MIGLYOL® 812. The buprenorphine-Glycerol di and tristearate (Bup-GDS-GTS) is provided in a range of 0.2 to 20 mg Bup-GDS-GTS to one ml (gram) MCT.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: September 17, 2024
    Inventor: Michael Guarnieri
  • Publication number: 20220064625
    Abstract: A method for forming a product from a gas includes flowing a gas through a bioreactor for contacting the gas with polymer-immobilized whole cells and collecting the product from the bioreactor. The bioreactor includes a plurality of printed three-dimensional structures, each printed three-dimensional structure having at least one sidewall being a lattice, and the polymer-immobilized whole cells being present in the lattice.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 3, 2022
    Inventors: Fang Qian, Sarah E. Baker, Joshua R. Deotte, Eric B. Duoss, Nathan C. Ellebracht, Jennifer Marie Knipe, Samantha Ruelas, Hawi Bacha Gemeda, Michael Guarnieri
  • Publication number: 20220047579
    Abstract: An injectable lipid-based suspension of buprenorphine providing one to seven days of pain alleviation has been developed. A method of manufacturing an injectable buprenorphine formulation providing about one to seven, preferably two to three, days of pain therapy, includes the steps of mixing buprenorphine and glyceryl tristearate dry powers, then mixing the resulting dry power blend with a liquid medium chain triglyceride (MCT), such as Miglyol 812, in a range of 0.2 to 20 mg Bup-GTS to one ml (or one gram) MCT.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 17, 2022
    Inventor: Michael Guarnieri
  • Publication number: 20190274874
    Abstract: The Transformation Chamber is unique in that it combines three additional elements to a regular cryotherapy session and is the last portion of the session. The Transformation Chamber has infrared and near infrared lighting that works in-conjunction with a guided meditation, and vibration. With all elements combined in one device allows client's to achieve more in less time in one place.
    Type: Application
    Filed: March 8, 2018
    Publication date: September 12, 2019
    Inventor: ANTHONY MICHAEL GUARNIERI
  • Publication number: 20190183832
    Abstract: Formulations and methods for reducing or preventing stress-related weight loss in animals have been developed. The formulations include medium-chain triglyceride (MCT) oil as the active agent. The methods include subcutaneously administering the formulation to an animal in need thereof shortly before, during, or after the stress. The stress may be due to restraint, surgery, injury, transportation, relocation, birth, separation, exercise, training, handling, rescue or other action that elicits stress or high energy expenditure or involves an animal with low energy reserves, such as a newborn or sick animal. The animals are typically agriculture animals, laboratory animals, veterinary animals, zoo animals, or pets. Also provided are kits containing ready-to-use dosage forms for reducing or preventing stress-related weight loss in animals.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 20, 2019
    Inventor: Michael Guarnieri
  • Patent number: 8461173
    Abstract: Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: June 11, 2013
    Assignee: The Johns Hopkins Univeristy
    Inventor: Michael Guarnieri
  • Patent number: 8093261
    Abstract: Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: January 10, 2012
    Assignee: The Johns Hopkins University
    Inventor: Michael Guarnieri
  • Publication number: 20110287101
    Abstract: Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry.
    Type: Application
    Filed: July 20, 2011
    Publication date: November 24, 2011
    Inventor: Michael Guarnieri
  • Publication number: 20080096910
    Abstract: Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry.
    Type: Application
    Filed: October 22, 2007
    Publication date: April 24, 2008
    Inventor: Michael Guarnieri
  • Patent number: 4172706
    Abstract: Trace amounts of carbonyl compounds, I, in aqueous solutions are analyzed by mixing the aqueous solution with radioactive derivatives of ammonia, II. Carbonyl compounds stoichiometrically react with derivatives of ammonia as follows ##EQU1## The weight of the parent compound, I is calculated from the radioactivity of the product, III, and the specific activity of II.The product is separated from the reaction mixture by chromatography or electrophoresis. The identity of I, if unknown, can be determined from the characteristic chromatographic or electrophoretic mobility of the derivative, III.The sensitivity of the method is determined by the specific activity of the radioactive chemical, II. Thus, if II contains 100 micro curies per micro mole, the process would detect 10.sup.-12 mole of carbonyl compound.
    Type: Grant
    Filed: August 4, 1977
    Date of Patent: October 30, 1979
    Inventor: Michael Guarnieri